ArticleDiscover oncology2026
Pan-cancer multi-dimensional characterization and biological significance of cholesterol 25-hydroxylase (CH25H).
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- SPP1 promotes lymph node metastasis and malignant progression of head and neck squamous cell carcinoma by activating FAK-AKT signaling pathway.World journal of surgical oncology · 2026Article
- Derivation and external validation of a prognostic nomogram for human epidermal growth factor receptor 2 negative early young breast cancer in women.Discover oncology · 2026Article
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- MiR-4725-3p acts as an oncogene and prognostic biomarker in hepatocellular carcinoma.World journal of surgical oncology · 2026Article
- Machine learning-guided multimodal profiling defines perturbed immune states at the time of cancer diagnosis.Briefings in bioinformatics · 2026Article
- Article
- Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCH25H encodes an interferon-inducible hydroxylase that converts cholesterol to 25-hydroxycholesterol (25-HC), linking lipid homeostasis to immune regulation. Its pan-cancer relevance remains incompletely defined.
methodsWe integrated TCGA/GTEx transcriptomes with TCGA copy-number, mutation and DNA-methylation data, and immune infiltration estimates (TIMER/MCP-COUNTER/ssGSEA). For each cancer type, overall survival was modeled by an identical multivariable Cox regression (high vs. low CH25H by within-cancer median) adjusting for age, sex and pathologic stage; proportional hazards were assessed.
resultsCH25H was dysregulated across multiple malignancies with tumor-type-specific directions. Copy-number losses and promoter hypermethylation jointly associated with reduced mRNA levels. Survival analyses revealed a context-dependent pattern: higher CH25H aligned with favorable outcomes in several immune-active tumors, but with poorer prognosis in selected gastrointestinal cancers. CH25H positively correlated with effector immune infiltration and IFN-γ-dominant/inflammatory immune subtypes. These directions were concordant with multivariable Cox estimates; full per-cancer results are provided in Supplementary Table S1.
conclusionsCH25H exhibits a context-dependent, biphasic role in cancer: on one hand, it may exert tumor-suppressive effects by enhancing anti-tumor immunity; on the other, it can promote tumor progression in specific cancer types or stages. Its expression is co-regulated by CNV and promoter methylation. CH25H and its enzymatic product, 25-HC, hold promise as both prognostic biomarkers and therapeutic targets in cancer immunotherapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.